Original articleTopical Interferon or Surgical Excision for the Management of Primary Ocular Surface Squamous Neoplasia
Section snippets
Materials and Methods
We performed a retrospective chart review of consecutive patients with primary OSSN (never before treated) presenting to the Dean McGee Eye Institute between January 1, 1996 and December 31, 2005. Institutional review board approval was obtained from the University of Oklahoma Health Sciences Center before initiation of the review. The initial diagnosis of OSSN was based on the ocular surface appearance at slit-lamp examination.4, 60 Patients diagnosed with primary OSSN chose either surgical
Results
Twenty-nine patients presenting between January 1, 1996 and December 31, 2005 were diagnosed with OSSN based on characteristic findings on slit-lamp examination—each patient had a raised epithelial lesion centered at the limbus with a leukoplakic, gelatinous, or papilliform appearance.4, 60 Of patients with primary OSSN, 15 elected to receive topical interferon alfa-2b and 14 elected to undergo excisional biopsy. Representative slit-lamp photographs before and after treatment are presented in
Discussion
Successful use of topical interferon alfa-2b as sole therapy for primary OSSN was previously reported in 15 patients in 5 previously published series (Table 3),50, 51, 52, 55, 58 with only 1 patient observed for more than 16 months.51 Our 13 patients successfully treated with topical interferon alfa-2b for primary OSSN bring the total number of patients in the published literature with primary OSSN successfully treated with topical interferon alfa-2b to 28, with a median disease-free follow-up
References (72)
- et al.
Ocular surface squamous neoplasia
Surv Ophthalmol
(1995) - et al.
Conjunctival and corneal intraepithelial and invasive neoplasia
Ophthalmology
(1986) - et al.
Risk factors in the development of ocular surface epithelial dysplasia
Ophthalmology
(1994) - et al.
Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia
Ophthalmology
(1999) - et al.
Human papillomavirus type 18 in conjunctival intraepithelial neoplasia
Am J Ophthalmol
(1990) - et al.
A spectrum of bilateral squamous conjunctival tumors associated with human papillomavirus type 16
Ophthalmology
(1991) - et al.
Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia
Ophthalmology
(2002) - et al.
Conjunctival malignant disease with AIDS in USA
Lancet
(1995) - et al.
HIV and conjunctival malignancies
Lancet
(1990) Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda
Lancet
(1995)
Management of intraepithelial conjunctival tumors and squamous cell carcinomas
Am J Ophthalmol
Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia
Ophthalmology
Mitomycin C therapy for corneal intraepithelial neoplasia
Am J Ophthalmol
Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia
Am J Ophthalmol
Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience
Ophthalmology
Mitomycin C treatment of conjunctival intraepithelial neoplasia
Am J Ophthalmol
Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C
Am J Ophthalmol
Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinoma
Am J Ophthalmol
Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasiaEarly resolution
Ophthalmology
Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea
Ophthalmology
5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea
Ophthalmology
Successful treatment with 5-fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C
Ophthalmology
Interferon treatment for corneolimbal squamous dysplasia
Am J Ophthalmol
Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b
Ophthalmology
Successful management of conjunctival intraepithelial neoplasia by interferon alpha-2b
Jpn J Ophthalmol
Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b
Ophthalmology
Management of conjunctival and corneal melanoma with surgical excision, amniotic membrane allograft, and topical chemotherapy
Am J Ophthalmol
HPV replication in experimental models: effects of interferon
Antiviral Res
Serious complications of topical mitomycin-C after pterygium surgery
Ophthalmology
Limbal stem cell deficiency following topical mitomycin C treatment of conjunctival-corneal intraepithelial neoplasia
Am J Ophthalmol
The aetiology and associations of conjunctival intraepithelial neoplasia
Br J Ophthalmol
Factors associated with conjunctival intraepithelial neoplasia: a case control study
Ophthalmic Surgery
DNA of human papillomavirus type 16 in dysplastic and malignant lesions of the conjunctiva and cornea
N Engl J Med
Carcinoma of the conjunctiva and HIV infection in Uganda and Malawi
Br J Ophthalmol
Conjunctival intraepithelial neoplasia: a possible marker for human immunodeficiency virus infection?
Arch Ophthalmol
Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997
Br J Cancer
Cited by (80)
Clinic-pathological agreement in the diagnosis of conjunctival tumours: Analysis of 195 cases
2023, Archivos de la Sociedad Espanola de OftalmologiaTreatment challenges associated with a superiorly located bulbar conjunctival mass—case report and review of the literature
2022, American Journal of Ophthalmology Case ReportsCitation Excerpt :Furthermore, different imaging techniques are usually beneficial to rule out the tumor's extension to adjacent structures.9 Treatment modalities for OSSN range from complete excision in focal and small tumors to administration of chemotherapeutic agents in diffuse and large lesions to a combination of both.7,10 The standard of care for treating OSSN appears to have undergone dramatic changes in the last two decades.
Ocular surface complications of local anticancer drugs for treatment of ocular tumors
2021, Ocular SurfaceCitation Excerpt :Conjunctivitis can arise from direct toxicities of anticancer drugs, vehicle and preservative, or can be caused by both allergic and non-allergic inflammation, manifesting as papillary and follicular conjunctivitis. Conjunctivitis was observed in 10–100% of eyes administered topical MMC [15,19,21–24,57,97,100–103], 20.4–100% topical 5-FU [35,37,39], 1–57.1% topical IFN-α2b [37,57–59,61,65,66,68,109,110], and 32–95% topical imiquimod [127,128,132,135]. Corneal epitheliopathy, ranging from superficial punctate keratitis to large persistent epithelial defects, can originate from drug toxicities to corneal epithelial cells and limbal epithelial stem cells or from drug-induced immune reactions.
Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia
2019, American Journal of OphthalmologyCitation Excerpt :Others have used a higher concentration (3 million IU/mL), with 1 study reporting a 100% resolution frequency after 2 months with no recurrences during a mean of 10.2 months follow-up using this higher concentration.31 Other studies, however, found no significant differences in efficacy by IFN concentrations.33,38 An advantage of IFN is its gentleness.
Ocular Tumors
2019, Abeloff’s Clinical Oncology
Manuscript no. 2007-1314.
Supported by a Physician–Scientist Merit Award (JC) and an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York, to the Department of Ophthalmology, University of Oklahoma.
The authors have no conflict of interest in the material presented in the article.